Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

Federica Marmorino, Lisa Salvatore, Cecilia Barbara, Giacomo Allegrini, Lorenzo Antonuzzo, Gianluca Masi, Fotios Loupakis, Beatrice Borelli, Silvana Chiara, Maria Chiara Banzi, Emanuela Miraglio, Domenico Amoroso, Francesco Dargenio, Andrea Bonetti, Angelo Martignetti, Myriam K. Paris, Daniela Tomcikova, Luca Boni, Alfredo Falcone, Chiara Cremolini

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. Methods: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy. A subgroup analysis according to baseline serum lactate dehydrogenase (LDH) levels was carried out. Results: A significant interaction effect between LDH levels and treatment was found in terms of progression-free survival (PFS; P=0.002). Although patients with low LDH levels achieved significant PFS benefit from the continuation of bevacizumab (HR: 0.39 (95% CI: 0.23-0.65)), patients with high levels did not (HR: 1.10 (95% CI: 0.74-1.64)). Consistent results were reported in overall survival (OS; P=0.075). Conclusions: As preclinical evidence suggests that serum LDH may be a marker of tumour angiogenesis activation, low levels may indicate that bevacizumab is still efficacious in inhibiting angiogenesis. Validation of present results in subgroup analyses of other randomised trials of second-line angiogenesis inhibitors is warranted.

Original languageEnglish
Pages (from-to)318-323
Number of pages6
JournalBritish Journal of Cancer
Volume116
Issue number3
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

L-Lactate Dehydrogenase
Colorectal Neoplasms
Serum
Angiogenesis Inhibitors
Therapeutics
Tumor Biomarkers
Disease-Free Survival
Drug Therapy
Survival
Bevacizumab

Keywords

  • bevacizumab beyond progression
  • LDH
  • predictive marker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Marmorino, F., Salvatore, L., Barbara, C., Allegrini, G., Antonuzzo, L., Masi, G., ... Cremolini, C. (2017). Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer, 116(3), 318-323. https://doi.org/10.1038/bjc.2016.413

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. / Marmorino, Federica; Salvatore, Lisa; Barbara, Cecilia; Allegrini, Giacomo; Antonuzzo, Lorenzo; Masi, Gianluca; Loupakis, Fotios; Borelli, Beatrice; Chiara, Silvana; Banzi, Maria Chiara; Miraglio, Emanuela; Amoroso, Domenico; Dargenio, Francesco; Bonetti, Andrea; Martignetti, Angelo; Paris, Myriam K.; Tomcikova, Daniela; Boni, Luca; Falcone, Alfredo; Cremolini, Chiara.

In: British Journal of Cancer, Vol. 116, No. 3, 01.01.2017, p. 318-323.

Research output: Contribution to journalArticle

Marmorino, F, Salvatore, L, Barbara, C, Allegrini, G, Antonuzzo, L, Masi, G, Loupakis, F, Borelli, B, Chiara, S, Banzi, MC, Miraglio, E, Amoroso, D, Dargenio, F, Bonetti, A, Martignetti, A, Paris, MK, Tomcikova, D, Boni, L, Falcone, A & Cremolini, C 2017, 'Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer', British Journal of Cancer, vol. 116, no. 3, pp. 318-323. https://doi.org/10.1038/bjc.2016.413
Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G et al. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer. 2017 Jan 1;116(3):318-323. https://doi.org/10.1038/bjc.2016.413
Marmorino, Federica ; Salvatore, Lisa ; Barbara, Cecilia ; Allegrini, Giacomo ; Antonuzzo, Lorenzo ; Masi, Gianluca ; Loupakis, Fotios ; Borelli, Beatrice ; Chiara, Silvana ; Banzi, Maria Chiara ; Miraglio, Emanuela ; Amoroso, Domenico ; Dargenio, Francesco ; Bonetti, Andrea ; Martignetti, Angelo ; Paris, Myriam K. ; Tomcikova, Daniela ; Boni, Luca ; Falcone, Alfredo ; Cremolini, Chiara. / Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. In: British Journal of Cancer. 2017 ; Vol. 116, No. 3. pp. 318-323.
@article{d7120865cd5a4993bf79d9c9413a9981,
title = "Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer",
abstract = "Background: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. Methods: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy. A subgroup analysis according to baseline serum lactate dehydrogenase (LDH) levels was carried out. Results: A significant interaction effect between LDH levels and treatment was found in terms of progression-free survival (PFS; P=0.002). Although patients with low LDH levels achieved significant PFS benefit from the continuation of bevacizumab (HR: 0.39 (95{\%} CI: 0.23-0.65)), patients with high levels did not (HR: 1.10 (95{\%} CI: 0.74-1.64)). Consistent results were reported in overall survival (OS; P=0.075). Conclusions: As preclinical evidence suggests that serum LDH may be a marker of tumour angiogenesis activation, low levels may indicate that bevacizumab is still efficacious in inhibiting angiogenesis. Validation of present results in subgroup analyses of other randomised trials of second-line angiogenesis inhibitors is warranted.",
keywords = "bevacizumab beyond progression, LDH, predictive marker",
author = "Federica Marmorino and Lisa Salvatore and Cecilia Barbara and Giacomo Allegrini and Lorenzo Antonuzzo and Gianluca Masi and Fotios Loupakis and Beatrice Borelli and Silvana Chiara and Banzi, {Maria Chiara} and Emanuela Miraglio and Domenico Amoroso and Francesco Dargenio and Andrea Bonetti and Angelo Martignetti and Paris, {Myriam K.} and Daniela Tomcikova and Luca Boni and Alfredo Falcone and Chiara Cremolini",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/bjc.2016.413",
language = "English",
volume = "116",
pages = "318--323",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

AU - Marmorino, Federica

AU - Salvatore, Lisa

AU - Barbara, Cecilia

AU - Allegrini, Giacomo

AU - Antonuzzo, Lorenzo

AU - Masi, Gianluca

AU - Loupakis, Fotios

AU - Borelli, Beatrice

AU - Chiara, Silvana

AU - Banzi, Maria Chiara

AU - Miraglio, Emanuela

AU - Amoroso, Domenico

AU - Dargenio, Francesco

AU - Bonetti, Andrea

AU - Martignetti, Angelo

AU - Paris, Myriam K.

AU - Tomcikova, Daniela

AU - Boni, Luca

AU - Falcone, Alfredo

AU - Cremolini, Chiara

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. Methods: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy. A subgroup analysis according to baseline serum lactate dehydrogenase (LDH) levels was carried out. Results: A significant interaction effect between LDH levels and treatment was found in terms of progression-free survival (PFS; P=0.002). Although patients with low LDH levels achieved significant PFS benefit from the continuation of bevacizumab (HR: 0.39 (95% CI: 0.23-0.65)), patients with high levels did not (HR: 1.10 (95% CI: 0.74-1.64)). Consistent results were reported in overall survival (OS; P=0.075). Conclusions: As preclinical evidence suggests that serum LDH may be a marker of tumour angiogenesis activation, low levels may indicate that bevacizumab is still efficacious in inhibiting angiogenesis. Validation of present results in subgroup analyses of other randomised trials of second-line angiogenesis inhibitors is warranted.

AB - Background: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. Methods: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy. A subgroup analysis according to baseline serum lactate dehydrogenase (LDH) levels was carried out. Results: A significant interaction effect between LDH levels and treatment was found in terms of progression-free survival (PFS; P=0.002). Although patients with low LDH levels achieved significant PFS benefit from the continuation of bevacizumab (HR: 0.39 (95% CI: 0.23-0.65)), patients with high levels did not (HR: 1.10 (95% CI: 0.74-1.64)). Consistent results were reported in overall survival (OS; P=0.075). Conclusions: As preclinical evidence suggests that serum LDH may be a marker of tumour angiogenesis activation, low levels may indicate that bevacizumab is still efficacious in inhibiting angiogenesis. Validation of present results in subgroup analyses of other randomised trials of second-line angiogenesis inhibitors is warranted.

KW - bevacizumab beyond progression

KW - LDH

KW - predictive marker

UR - http://www.scopus.com/inward/record.url?scp=85009376654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009376654&partnerID=8YFLogxK

U2 - 10.1038/bjc.2016.413

DO - 10.1038/bjc.2016.413

M3 - Article

VL - 116

SP - 318

EP - 323

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -